2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide - Names and Identifiers
2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide - Physico-chemical Properties
Molecular Formula | C24H30ClN7O2S
|
Molar Mass | 516.06 |
Density | 1.347±0.06 g/cm3(Predicted) |
Melting Point | >198°C (dec.) |
Boling Point | 664.7±65.0 °C(Predicted) |
Solubility | DMSO: ≥ 30 mg/mL |
Appearance | Solid |
Color | Off-White to Light Yellow |
pKa | 7.60±0.10(Predicted) |
Storage Condition | Hygroscopic, -20°C Freezer, Under inert atmosphere |
Use | Dubermatinib (TP-0903) is an efficient and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM. |
Target | AXL |
In vitro study | In pancreatic cancer cells (PSN-1), TP-0903 showed a strong antiproliferative activity with an IC50 of 6 M. TP-0903 induced A strong G2/M blockade by potent inhibition of Aurora A and B. In CLL B cells from CLL patients, TP-0903 induced massive apoptosis in a dose-dependent manner by targeting phosphorylated Axl and overcame the CLL BMSC-mediated protective effect on CLL B cell apoptosis. |
In vivo study | In the adult rat hippocampus, intracerebroventricular administration of SAG (2.5 nM) significantly increased the number of new cells and prolonged the survival of hippocampal cells. In mice, SAG (20 μg/g, I. p.) effectively prevents GC-induced neonatal cerebellar dysplasia. |
2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide - Reference
Reference Show more | 1 Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ. Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett. 2011 Dec 8;2(12):907-912.2 ToleroPharmaceuticals, Inc–TP-0903. http://www.toleropharmaceuticals.com/TP-0903.html. |
2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 1.938 ml | 9.689 ml | 19.378 ml |
5 mM | 0.388 ml | 1.938 ml | 3.876 ml |
10 mM | 0.194 ml | 0.969 ml | 1.938 ml |
5 mM | 0.039 ml | 0.194 ml | 0.388 ml |
Last Update:2024-01-02 23:10:35
2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide - Cell Experiment
For cell proliferation assays, 45 μL containing 1000 cells per well are seeded into solid white 384-well plates in appropriate media. The following day, TP-0903 is diluted in serum free growth media to 10x desired concentrations and 5 μL is added to each well. Combined compound and cells are incubated for 96 hours. Following incubation, 40 μL of ATP-Lite solution is added to each well, incubated for an additional 10 minutes at room temperature and luminescence is measured on an microplate reader
Last Update:2023-08-16 21:32:38